Market Signal Briefing

Alcon (ALC - Free Report) reported $2.7 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 9.1%. EPS of $0.78 for the same period compares to $0.72 a year ago.

The reported revenue represents a surprise of -0.2% over the Zacks Consensus Estimate of $2.71 billion. With the consensus EPS estimate being $0.79, the EPS surprise was -0.76%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- Total Surgical- Equipment/other: $277 million compared to the $277.54 million average estimate based on four analysts. The reported number represents a change of +21% year over year.Net Sales- Total Surgical- Implantables: $474 million versus $482.1 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4% change.Net Sales- Total Surgical: $1.55 billion compared to the $1.56 billion average estimate based on four analysts. The reported number represents a change of +8.6% year over year.Net Sales- Total Vision care: $1.16 billion versus the four-analyst average estimate of $1.15 billion. The reported number represents a year-over-year change of +9.8%.Net Sales- Total Surgical- Consumables: $794 million versus the four-analyst average estimate of $796.13 million. The reported number represents a year-over-year change of +7.6%.Net Sales- Total Vision Care- Contact lenses: $683 million compared to the $687.14 million average estimate based on four analysts. The reported number represents a change of +7.1% year over year.Net Sales- Total Vision Care- Ocular health: $474 million compared to the $462.7 million average estimate based on four analysts. The reported number represents a change of +13.9% year over year.Net Sales and other revenues- Other revenues: $16 million versus $26.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -36% change.Net Sales and other revenues- Net Sales: $2.7 billion versus $2.7 billion estimated by three analysts on average.View all Key Company Metrics for Alcon here>>>

Shares of Alcon have returned +2.6% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

For the quarter ended December 2025, MercadoLibre (MELI - Free Report) reported revenue of $8.76 billion, up 44.6% over the same period last year. EPS came in at $11.03, compared to $12.61 in the year-ago quarter.

The reported revenue represents a surprise of +2.86% over the Zacks Consensus Estimate of $8.52 billion. With the consensus EPS estimate being $11.77, the EPS surprise was -6.31%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how MercadoLibre performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Gross merchandise volume: $19.91 billion versus $19.19 billion estimated by four analysts on average.Total payment volume: $83.69 billion compared to the $82.19 billion average estimate based on three analysts.Geographic Revenue- Brazil: $4.64 billion versus $4.48 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +47.9% change.Geographic Revenue- Other countries: $414 million versus $387.14 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +53.9% change.Geographic Revenue- Mexico: $2.1 billion versus $2.13 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +55.6% change.Geographic Revenue- Argentina: $1.61 billion versus $1.67 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +23.3% change.View all Key Company Metrics for MercadoLibre here>>>

Shares of MercadoLibre have returned -15.7% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

For the quarter ended December 2025, SPX Technologies (SPXC - Free Report) reported revenue of $637.3 million, up 19.4% over the same period last year. EPS came in at $1.88, compared to $1.51 in the year-ago quarter.

The reported revenue represents a surprise of +1.57% over the Zacks Consensus Estimate of $627.44 million. With the consensus EPS estimate being $1.86, the EPS surprise was +0.92%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how SPX Technologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Detection & Measurement: $206.2 million versus $197.64 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +26.4% change.Revenues- HVAC: $431.1 million versus the five-analyst average estimate of $429.8 million. The reported number represents a year-over-year change of +16.4%.Segment Income- Detection & Measurement: $47.9 million compared to the $45.83 million average estimate based on four analysts.Segment Income- HVAC: $108.5 million compared to the $107.68 million average estimate based on four analysts.View all Key Company Metrics for SPX Technologies here>>>

Shares of SPX Technologies have returned +10.2% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

For the quarter ended December 2025, Flywire (FLYW - Free Report) reported revenue of $152.7 million, up 35.4% over the same period last year. EPS came in at $0, compared to -$0.12 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $143.83 million, representing a surprise of +6.17%. The company delivered an EPS surprise of +100%, with the consensus EPS estimate being -$0.01.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Flywire performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Total Payment Volume: $9.3 billion compared to the $8.24 billion average estimate based on five analysts.Revenue- Transaction: $126.5 million compared to the $117.36 million average estimate based on four analysts. The reported number represents a change of +32.7% year over year.Revenue Less Ancillary Services- Transaction: $126 million compared to the $117.9 million average estimate based on four analysts. The reported number represents a change of +32.6% year over year.Revenue Less Ancillary Services- Platform and other revenues: $26.7 million versus $23.18 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +50% change.Revenue- Platform and other revenues: $31 million versus the four-analyst average estimate of $26.21 million. The reported number represents a year-over-year change of +39%.View all Key Company Metrics for Flywire here>>>

Shares of Flywire have returned -22.6% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Insider buying is one of the best bullish indicators out there, and this AI company has seen some serious activity recently.

Insider buying is one of the best indicators of how a stock might perform in the future.

The people running a company or who sit on its board of directors know it best. How could they not? They know things an investor couldn't, like sales figures since the last quarterly report or total intangibles you can't put on a spreadsheet, like office morale.

It was once put very succinctly by investing legend Peter Lynch: "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise."

So, if you're worried about an artificial intelligence (AI) bubble and want to know which AI companies are the real deal versus those facing a rude awakening if/when any AI bubble pops, look at what the insiders at AI companies are doing with their money.

And there is one AI company that has seen some rather promising insider activity in recent months.

Image source: Getty Images.

A force for sales, a Salesforce if you will Salesforce (CRM +4.18%) is a fundamentally strong company, but its shares have had a rough go on the market recently. The company is down 30% year to date (as of Feb. 19.

There hasn't been much insider activity recently, only four transactions with two buys and two sells, but what is there is interesting.

First was Harris Parker, the company's co-founder. His sale of $31.6 million in shares in December 2025 may look alarming at first, but that transaction was part of a 10b5-1 plan, which means it was pre-planned and unrelated to Salesforce's performance.

The only other sale (and the only discretionary sale) was from Neelie Kroes, former VP of the European Commission and a longtime Salesforce director. She sold 3,893 shares for a total of $929,276 in January 2026. As I mentioned before, though, sales like that could be for any number of reasons.

Today's Change

(

4.18

%) $

7.45

Current Price

$

185.61

On to the buyers, with two interesting transactions.

The smaller purchase involved Kirk David Blair, a company director. He bought 1,936 shares for a total of $500,722 in mid-December 2025. That's a serious vote of confidence in where Salesforce is headed in its near future.

But the biggest play was from Mason Morfit, another director and the co-chief executive officer and chief investment officer of the investment firm ValueAct Capital with $10 billion in assets under management. Or rather, his firm bought some Salesforce stock.

ValueAct purchased $25 million worth of Salesforce shares on Dec. 5 , showing serious confidence in Salesforce's future.

So, excluding the 10b5-1 sales, which didn't concern Salesforce as a company, there's net insider buying totaling just shy of $24.6 million in the past three months.

With that in mind, I am very interested in Salesforce's fiscal 2026 results, which are due to be released on Feb. 25, and its spring 2026 product release on Feb. 23, 2026, when it plans to introduce new agentic capabilities and an AI-powered Sales Workspace, among other things.

Just because company insiders know more than outside investors about what's going on behind the scenes doesn't mean they're right about everything. High insider buying activity isn't a foolproof indicator. However, combined with Salesforce's fundamental strength, I would recommend giving this one a look.

Tigo Energy, Inc. (TYGO - Free Report) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.44 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +18.26%. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.03, delivering a surprise of +40%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Tigo Energy, Inc., which belongs to the Zacks Solar industry, posted revenues of $30.03 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.32%. This compares to year-ago revenues of $17.27 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Tigo Energy, Inc. shares have added about 142.8% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for Tigo Energy, Inc.?While Tigo Energy, Inc. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Tigo Energy, Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.08 on $26.25 million in revenues for the coming quarter and -$0.11 on $128.02 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Solar is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, FTC Solar (FTCI - Free Report) , has yet to report results for the quarter ended December 2025. The results are expected to be released on March 5.

This solar tracking systems maker is expected to post quarterly loss of $0.21 per share in its upcoming report, which represents a year-over-year change of +73.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

FTC Solar's revenues are expected to be $32.83 million, up 148.7% from the year-ago quarter.

UFP Technologies (UFPT - Free Report) came out with quarterly earnings of $2.44 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.46 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +7.81%. A quarter ago, it was expected that this packaging company and component manufacturer would post earnings of $2.22 per share when it actually produced earnings of $2.39, delivering a surprise of +7.66%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

UFP, which belongs to the Zacks Medical - Instruments industry, posted revenues of $148.92 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 1.08%. This compares to year-ago revenues of $144.07 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

UFP shares have added about 8.9% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for UFP?While UFP has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for UFP was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.55 on $156.63 million in revenues for the coming quarter and $10.58 on $635.48 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Treace Medical Concepts (TMCI - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2025. The results are expected to be released on February 27.

This orthopedic medical device maker is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of -1400%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Treace Medical Concepts' revenues are expected to be $61.77 million, down 10.1% from the year-ago quarter.

STAMFORD, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential breaches of fiduciary duty by the Board of Directors of MarketWise, Inc. (Nasdaq: MKTW) on behalf of the company's stockholders.

The investigation focuses on whether the MarketWise Board of Directors has fulfilled its fiduciary obligations to stockholders, including its duty of loyalty.

Stockholders who have held shares of MarketWise and are interested in learning more about the investigation or their legal rights are encouraged to contact Abbott Cooper PLLC at no cost or obligation.

Abbott Cooper PLLC handles cases on a contingency fee basis, meaning there is no cost to stockholders unless a recovery is obtained.

IF YOU ARE A MARKETWISE STOCKHOLDER AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, PLEASE CONTACT:

J. Abbott R. Cooper
Abbott Cooper PLLC
1266 East Main Street
Suite 700R
Stamford, CT 06902
(475) 477-5031
[email protected]
https://abbottlawyer.com/

Attorney Advertising. Prior results do not guarantee a similar outcome.

Tempus AI, Inc. (TEM) Q4 2025 Earnings Call Transcript

, /PRNewswire/ -- IBM (NYSE: IBM) today released the 2026 X-Force Threat Intelligence Index, revealing that cybercriminals are exploiting basic security gaps at dramatically higher rates, now accelerated by AI tools that help attackers identify weaknesses faster than ever. IBM X‑Force observed a 44% increase in attacks that began with the exploitation of public-facing applications, largely driven by missing authentication controls and AI-enabled vulnerability discovery. 

Some of the key highlights include:

IBM X-Force Threat Intelligence Index 2026 Active ransomware and extortion groups surged (49%) year over year, marking ecosystem fragmentation, while publicly disclosed victim counts rose roughly 12%. Large supply chain and third-party compromises nearly quadrupled since 2020, as attackers increasingly exploit environments where software is built and deployed or SaaS integrations. Vulnerability exploitation became the leading cause of attacks, accounting for 40% of incidents observed by X-Force in 2025. "Attackers aren't reinventing playbooks, they're speeding them up with AI," said Mark Hughes, Global Managing Partner for Cybersecurity Services, IBM. "The core issue is the same: businesses are overwhelmed by software vulnerabilities. The difference now is speed. With so many vulnerabilities requiring no credentials, attackers can bypass humans and move straight from scanning to impact. Security leaders need to shift to a more proactive approach, using agentic-powered threat detection and response to identify gaps and catch threats before they escalate."

AI's Mounting Identity Problem

Infostealer malware led to the exposure of over 300,000 ChatGPT credentials in 2025, signaling that AI platforms have reached the same credential risk as other core enterprise SaaS solutions.

Compromised chatbot credentials create AI-specific risks beyond simple account access. Attackers can manipulate outputs, exfiltrate sensitive data or inject malicious prompts. This underscores the need to assess enterprise-wide AI adoption and enforce strong authentication, and conditional access controls.

AI, Leaked Tooling Lower Barriers to Ransomware Ecosystem

In 2025, X-Force observed a 49% increase in active ransomware groups compared to the prior year, as smaller, transient operators whose low volume campaigns complicate attribution. This trend is accelerated by collapsing barriers to entry as threat actors reuse leaked tooling, rely on established playbooks and increasingly tap AI to automate operations. As multimodal AI models mature, X-Force expects adversaries to automate complex tasks like reconnaissance and advanced ransomware attacks, driving faster-moving, more adaptive threats.

Pressure on Supply Chains Poised to Grow

X-Force identified a nearly 4X increase in large supply chain or third-party compromises since 2020, mainly driven by attackers exploiting trust relationships and CI/CD automation across development workflows and SaaS integrations. With AI-powered coding tools accelerating software creation, and occasionally introducing unvetted code, the pressure on pipelines and open‑source ecosystems is expected to grow in 2026.

This rise is also attributed to the blurring line between nation-state and financially motivated actors. As tactics and techniques spread across underground forums, and AI streamlines reconnaissance and exploitation, techniques once reserved for nation-state actors are now being adopted by financially motivated groups.

Additional findings from the 2026 report include:

AI accelerating attacker lifecycle. Attackers are using AI to speed research, analyze large data sets and iterate on attack paths in real time. For example, North Korean IT worker schemes are using AI to scale operations, including AI-driven image manipulation for synthetic identities and translation tools to interact across global marketplaces. Security fundamentals still lacking. X-Force Red penetration tests reveal persistent weaknesses in credential hygiene and software configuration, with misconfigured access controls as the most common entry point for these engagements. Manufacturing tops the target list for the fifth year. The sector accounted for 27.7% of incidents observed by X-Force, with data theft being the most common. North America emerged as the most‑attacked region. Accounting for 29% of total cases observed by X-Force, and up from 24% in 2024, North America became the most attacked region for the first time in 6 years. Additional resources:

Read the full IBM X-Force Threat Intelligence Index 2026. Sign up for the IBM X-Force Threat Intelligence 2026 webinar on March 17 at 11 am ET. Connect with the IBM X-Force team for a tailored review of the findings. Read more about the report's top findings in this blog. About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain a competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

Media Contact:
Michele Brancati
IBM Communications
[email protected]

SOURCE IBM

Marqeta (MQ - Free Report) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +100.00%. A quarter ago, it was expected that this transaction processing services provider would post a loss of $0.01 per share when it actually produced a loss of $0.01, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Marqeta, which belongs to the Zacks Financial Transaction Services industry, posted revenues of $172.11 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.94%. This compares to year-ago revenues of $135.79 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Marqeta shares have lost about 13.9% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for Marqeta?While Marqeta has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Marqeta was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is breakeven on $167.54 million in revenues for the coming quarter and $0.04 on $737.73 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial Transaction Services is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

DLocal (DLO - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2025. The results are expected to be released on March 18.

This online payment company is expected to post quarterly earnings of $0.18 per share in its upcoming report, which represents a year-over-year change of +20%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

DLocal's revenues are expected to be $295.98 million, up 44.7% from the year-ago quarter.

Hyliion Holdings Corp. (HYLN - Free Report) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +12.50%. A quarter ago, it was expected that this company would post a loss of $0.08 per share when it actually produced a loss of $0.08, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Hyliion, which belongs to the Zacks Automotive - Original Equipment industry, posted revenues of $0.71 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 43.04%. This compares to year-ago revenues of $1.51 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Hyliion shares have added about 6% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for Hyliion?While Hyliion has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Hyliion was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.08 on $1.5 million in revenues for the coming quarter and -$0.32 on $14.25 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Automotive - Original Equipment is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Custom Truck One Source, Inc. (CTOS - Free Report) , is yet to report results for the quarter ended December 2025. The results are expected to be released on March 10.

This company is expected to post quarterly earnings of $0.09 per share in its upcoming report, which represents a year-over-year change of +125%. The consensus EPS estimate for the quarter has been revised 1.3% lower over the last 30 days to the current level.

Custom Truck One Source, Inc.'s revenues are expected to be $581.67 million, up 11.7% from the year-ago quarter.

LTC Properties (LTC - Free Report) came out with quarterly funds from operations (FFO) of $0.7 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to FFO of $0.72 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an FFO surprise of +2.32%. A quarter ago, it was expected that this real estate investment trust would post FFO of $0.65 per share when it actually produced FFO of $0.69, delivering a surprise of +6.15%.

Over the last four quarters, the company has surpassed consensus FFO estimates three times.

LTC, which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $26.71 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 6.02%. This compares to year-ago revenues of $34.81 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.

LTC shares have added about 14% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for LTC?While LTC has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for LTC was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.72 on $32.68 million in revenues for the coming quarter and $2.80 on $138.65 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, VICI Properties Inc. (VICI - Free Report) , has yet to report results for the quarter ended December 2025. The results are expected to be released on February 25.

This company is expected to post quarterly earnings of $0.60 per share in its upcoming report, which represents a year-over-year change of +5.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

VICI Properties Inc.'s revenues are expected to be $1.02 billion, up 4.1% from the year-ago quarter.

Corcept Therapeutics (CORT - Free Report) came out with quarterly earnings of $0.2 per share, missing the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -24.53%. A quarter ago, it was expected that this drug developer would post earnings of $0.18 per share when it actually produced earnings of $0.16, delivering a surprise of -11.11%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Corcept, which belongs to the Zacks Medical - Drugs industry, posted revenues of $202.13 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 20.54%. This compares to year-ago revenues of $181.89 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Corcept shares have added about 1.6% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for Corcept?While Corcept has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Corcept was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.26 on $195.52 million in revenues for the coming quarter and $0.72 on $1.03 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Aclaris Therapeutics (ACRS - Free Report) , is yet to report results for the quarter ended December 2025.

This specialty pharmaceutical company is expected to post quarterly loss of $0.15 per share in its upcoming report, which represents a year-over-year change of -50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Aclaris Therapeutics' revenues are expected to be $1.93 million, down 79% from the year-ago quarter.

FrontView REIT, Inc. (FVR - Free Report) came out with quarterly funds from operations (FFO) of $0.31 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.27 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an FFO surprise of +1.08%. A quarter ago, it was expected that this company would post FFO of $0.3 per share when it actually produced FFO of $0.32, delivering a surprise of +6.67%.

Over the last four quarters, the company has surpassed consensus FFO estimates four times.

FrontView REIT, Inc., which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $16.52 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 2.97%. This compares to year-ago revenues of $16.87 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.

FrontView REIT, Inc. shares have added about 11.6% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for FrontView REIT, Inc.?While FrontView REIT, Inc. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for FrontView REIT, Inc. was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.31 on $17.66 million in revenues for the coming quarter and $1.29 on $74.32 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Hudson Pacific Properties (HPP - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2025. The results are expected to be released on February 26.

This real estate investment trust is expected to post quarterly earnings of $0.20 per share in its upcoming report, which represents a year-over-year change of -74%. The consensus EPS estimate for the quarter has been revised 26.8% lower over the last 30 days to the current level.

Hudson Pacific Properties' revenues are expected to be $189.59 million, down 9.6% from the year-ago quarter.

Evolent Health (EVH - Free Report) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +28.00%. A quarter ago, it was expected that this health care software and consulting services provider would post earnings of $0.1 per share when it actually produced earnings of $0.05, delivering a surprise of -50%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Evolent Health, which belongs to the Zacks Medical Info Systems industry, posted revenues of $468.72 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.11%. This compares to year-ago revenues of $646.54 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Evolent Health shares have lost about 30.8% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for Evolent Health?While Evolent Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Evolent Health was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.08 on $544.44 million in revenues for the coming quarter and $0.39 on $2.39 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, KORU Medical Systems, Inc. (KRMD - Free Report) , has yet to report results for the quarter ended December 2025.

This company is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of +33.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

KORU Medical Systems, Inc.'s revenues are expected to be $10.89 million, up 23.2% from the year-ago quarter.

AbCellera Biologics Inc. (ABCL - Free Report) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +83.56%. A quarter ago, it was expected that this company would post a loss of $0.17 per share when it actually produced a loss of $0.19, delivering a surprise of -11.76%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

ABCELLERA BIOLG, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $44.85 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 565.48%. This compares to year-ago revenues of $5.05 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

ABCELLERA BIOLG shares have lost about 11.4% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for ABCELLERA BIOLG?While ABCELLERA BIOLG has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for ABCELLERA BIOLG was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.16 on $16.81 million in revenues for the coming quarter and -$0.67 on $57.07 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, CytomX Therapeutics (CTMX - Free Report) , has yet to report results for the quarter ended December 2025.

This biopharmaceutical company is expected to post quarterly loss of $0.08 per share in its upcoming report, which represents a year-over-year change of -136.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

CytomX Therapeutics' revenues are expected to be $7.35 million, down 80.7% from the year-ago quarter.

CeriBell, Inc. (CBLL - Free Report) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +16.76%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.37, delivering a surprise of +13.95%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

CeriBell, Inc., which belongs to the Zacks Medical - Products industry, posted revenues of $24.78 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.40%. This compares to year-ago revenues of $18.53 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

CeriBell, Inc. shares have lost about 8.9% since the beginning of the year versus the S&P 500's decline of 0.1%.

What's Next for CeriBell, Inc.?While CeriBell, Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for CeriBell, Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.37 on $26.01 million in revenues for the coming quarter and -$1.46 on $112.76 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 45% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Agilent Technologies (A - Free Report) , has yet to report results for the quarter ended January 2026. The results are expected to be released on February 25.

This scientific instrument maker is expected to post quarterly earnings of $1.37 per share in its upcoming report, which represents a year-over-year change of +4.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Agilent Technologies' revenues are expected to be $1.8 billion, up 7.3% from the year-ago quarter.

Seagate has been re-rated in the last 6 months as an AI data center infrastructure bet in the HDD memory space. Perception changed, but revenue growth is still far from Micron and SanDisk, as HDD is seeing fewer price hikes than SSDs or DRAM/HBM chips. That said, STX delivered its highest free cash flow in eight years and guided above consensus, with 87% of exabyte shipments now data center-driven.

Amplitude Energy Limited (COPJF) Q2 2026 Earnings Call February 24, 2026 5:00 PM EST

Company Participants

Jane Norman - MD, CEO & Director
Ian Bucknell - Chief Financial Officer
Chad Wilson - Chief Operating Officer

Conference Call Participants

Gordon Ramsay - RBC Capital Markets, Research Division
Dale Koenders - Barrenjoey Markets Pty Limited, Research Division
Nik Burns - Jarden Limited, Research Division
James Bullen - Canaccord Genuity Corp., Research Division
Declan Bonnick - Euroz Hartleys Securities Limited, Research Division

Presentation

Operator

Welcome to the Amplitude Energy Limited FY '26 First Half Results Webcast. [Operator Instructions]

I will now pass over to Jane Norman, Managing Director and Chief Executive Officer of Amplitude Energy. Please go ahead, Jane.

Jane Norman
MD, CEO & Director

Good morning, and thank you for joining us. This is Jane Norman, and I'm joined today by our Chief Operating Officer, Chad Wilson; and our new Chief Financial Officer, Ian Bucknell.

For those who haven't yet met Ian, he started with Amplitude as our CFO in January this year. Ian has held several prior CFO roles at ASX-listed energy and mining companies over the last 15 years, and we are very pleased to have someone of his caliber add to the strength of the executive team. Ian will cover our first half financial results in detail a little later on.

After today's presentation, we will host a Q&A session, and we welcome your questions. Today's presentation as well as our first half financial report and summary announcement were released to the ASX this morning and are available on the Amplitude Energy website. Today's webcast is being recorded, and a playback will be available on our website later today.

Please note the disclaimer information on Slide 2 of the presentation before moving on to Slide 3.

I'll come to our record first half

TBC Bank Group PLC (TBCCF) Strategy Day: Discusses Group Strategic Plans and Regional Focus on Georgia and Uzbekistan Transcript

Agora is transitioning from audio/video services to a leading Conversational AI Infrastructure provider, leveraging its proprietary SD-RTN network and AI Engine 2.0. API achieved its fourth consecutive quarter of revenue growth, posting $35.4 million in Q3 with 12% YoY growth and a return to net profitability. Significant restructuring improved operational efficiency, reducing R&D to 39% of revenue and administrative expenses by half, while maintaining $374 million in liquidity.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardent To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Ardent between July 18, 2024 and November 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - February 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardent Health, Inc. ("Ardent" or the "Company") (NYSE: ARDT) and reminds investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: During the Class Period, Defendants publicly reported the Company's accounts receivable on a quarterly basis. They further stated that Ardent Health employed an active monitoring process to determine the collectability of its accounts receivable, and that this process included "detailed reviews of historical collections" as a "primary source of information." Further, Defendants represented that Ardent Health considered "trends in federal and state governmental healthcare coverage" and that its "management determines [when an] account is uncollectible, at which time the account is written off

On November 12, 2025, after market hours, Ardent Health revealed a $43 million decrease in third quarter 2025 revenue. The decrease resulted from revised determinations of accounts receivable collectability after the Company transitioned to a new revenue accounting system and from purported "recently completed hindsight evaluations of historical collection trends." The new system-called the Kodiak RCA net revenue platform-provided management with "additional information to more precisely" determine accounts receivable collectability, including "more timely consideration of payor denial and payment trends." Defendant Lumsdaine revealed that the new system "recognizes reserves earlier in an account's life cycle" compared to the Company's prior -5- collectability framework, which "had utilized a 180-day cliff at which time an account became fully reserved."

Ardent Health also announced a cut to 2025 EBITDA guidance of $57.5 million at the midpoint, or about 9.6%, from $575 million - $625 million to $530 million - $555 million because of "persistent industry-wide cost pressures," including "payer denials." In addition, Ardent Health recorded a $54 million increase in professional liability reserves "with respect to recent settlements and ongoing litigation arising from a limited set of claims between 2019 and 2022 in New Mexico" as well as "consideration of broader industry trends, including social inflationary pressures."

On this news, the price of Ardent Health stock fell $4.75 per share, or nearly 34%,

from $14.05 per share on November 12, 2025, to close at $9.30 per share on November 13, 2025,

on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ardent's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Ardent Health class action, go to www.faruqilaw.com/ARDT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285105

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

By PYMNTS  |  February 24, 2026

 | 

Coinbase now offers stock trading to everyone in the United States, allowing its users to trade stocks and exchange-traded funds (ETFs) alongside the crypto the platform already handled.

This move is part of the company’s Everything Exchange vision in which it aims to encompass all asset classes and build the next generation of markets, Coinbase said in a Tuesday (Feb. 24) blog post.

Coinbase’s new stock trading offering lets users buy, sell and manage stocks and ETFs 24 hours a day, five days a week, according to the post. Users can fund their trades instantly with U.S. dollars and USDC stablecoins.

“We’re starting with the world’s leading equities and plan to expand 24/5 trading to thousands more stocks over the coming months,” Coinbase said in the post. “This spring, Coinbase also plans to broaden stock perpetuals, enabling traders outside the U.S. to get 24/7, capital-efficient exposure to U.S. equities.”

We’d love to be your preferred source for news.

Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

Coinbase also announced in the post that it has partnered with Yahoo Finance to enable users who are researching an asset on Yahoo Finance to execute a trade on Coinbase with one click.

In addition, Yahoo Finance will incorporate real-time information from Coinbase into its site, which offers financial news, data and personal finance tools, according to the post. This integration will make it easier for users to discover and monitor assets, per the post.

Advertisement: Scroll to Continue

“This partnership ensures traders have the resources they need to thrive in an increasingly ‘always-on’ market across asset classes,” Coinbase said in the post.

Coinbase executives said during an October earnings call that the Everything Exchange concept is central to the company’s current narrative. The concept combines three layers of activity: trading, financial services and applications. The strategy aims to attract users through regulated spot and derivatives markets; retain them with financial utilities such as custody, rewards and lending; and provide infrastructure and developer tools for on-chain applications that can expand overall network demand.

During a Feb. 12 earnings call, executives highlighted the platform’s diversification plays.

“The Everything Exchange is working,” Coinbase CEO Brian Armstrong said during the call. “In 2025, we drove all-time highs across our products: Coinbase One subscriptions reached ~1 million, trading volume and market share doubled, and USDC held on platform reached an all-time high.”

NEW YORK and NEW ORLEANS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Ultragenyx who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-rare/

Ultragenyx investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-rare/ to learn more.

CASE DETAILS:   On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.”   On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.

The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.

WHAT TO DO? If you invested in Ultragenyx and suffered a loss during the relevant time frame, you have until April 6, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn